SLAS 2019 Advanced 3D Human Models and High-Content Analysis Symposium

3D cellular models represent a fantastic opportunity for pharmaceutical industries to improve their discovery pipeline efficacy by bringing potentially much more relevant models within the early stages of the workflow. Moreover, it has been shown that in specific cases 2D and 3D models response to drug treatment can strongly vary and thus impact the in vitro relevance of the physiopathological model associated readouts. This approach is particularly well suited for complex or partially characterized targets in oncology. In this context, we have performed a systematic comparison of the 2D vs. 3D high content imaging readouts using a single cancer cell line. We will discuss about the challenges associated to such large scale screening in term of cellular processing but also in term of image and data analysis. Ultimately, we will discuss about the results generated from such a comparative study.